262 related articles for article (PubMed ID: 15032288)
21. P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer.
Sagarra RA; Andrade LA; Martinez EZ; Pinto GA; Syrjänen KJ; Derchain SF
Int J Gynecol Cancer; 2002; 12(6):720-7. PubMed ID: 12445249
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
23. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
[TBL] [Abstract][Full Text] [Related]
24. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
25. DEF6 expression in ovarian carcinoma correlates with poor patient survival.
Liew PL; Fang CY; Lee YC; Lee YC; Chen CL; Chu JS
Diagn Pathol; 2016 Aug; 11(1):68. PubMed ID: 27488395
[TBL] [Abstract][Full Text] [Related]
26. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
El-Husseiny K; Motawei H; Ali MS
Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
[TBL] [Abstract][Full Text] [Related]
27. Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients.
Molckovsky A; Vijay SM; Hopman WM; Bryson P; Jeffrey JF; Biagi JJ
Int J Gynecol Cancer; 2008; 18(1):8-13. PubMed ID: 17511802
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
29. Value of glutathion-S transferase pi as a prognostic factor in epithelial ovarian carcinoma.
Saip P; Tuzlali S; Demir K; Sakar B; Yavuz E; Berkman S; Bengisu E; Topuz E
Eur J Gynaecol Oncol; 2005; 26(1):90-4. PubMed ID: 15755010
[TBL] [Abstract][Full Text] [Related]
30. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
31. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
32. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
33. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
34. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
36. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
37. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Whynott RM; Manahan P; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
[TBL] [Abstract][Full Text] [Related]
39. Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Komiyama S; Kurahashi T; Ishikawa M; Tanaka K; Komiyama M; Mikami M; Udagawa Y
Oncol Rep; 2011 Apr; 25(4):1131-8. PubMed ID: 21249319
[TBL] [Abstract][Full Text] [Related]
40. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]